MGM-16, MGM-15, and 7-OH: Understanding the New Generation of Semi-Synthetic Kratom Opioids
MGM-16, MGM-15, and 7-OH: Florida’s Emergency Rule and the Rise of Semi-Synthetic Kratom Opioids
By Benjamin Zohar, NCACIP
Medically reviewed by Brandon McNally, RN
Last Updated: July 2026
Table of Contents
- Key Takeaways
- The Bigger Picture: A Synthetic Turning Point
- What Is MGM-16?
- MGM-16 vs. What Is Actually on Shelves
- Comparison of 7-OH-Related Compounds
- Why Officials Are Sounding the Alarm
- Florida’s 2026 Emergency Rule
- DEA 2026 Federal Update
- If You or Someone You Love Is Using 7-OH Products
- Related Articles
- Disclaimer
Key Takeaways
- Florida’s June 2026 emergency rule did not target only 7-hydroxymitragynine. It also named related compounds including mitragynine pseudoindoxyl, 7-acetoxymitragynine, MGM-15, and MGM-16.
- MGM-16 is a semi-synthetic kratom-derived opioid compound, not a natural component of kratom leaf.
- 7-OH and MGM-15 are the compounds most relevant to the current commercial market, while MGM-16 represents the more potent edge of this chemical family.
- Concentrated 7-OH products are pharmacologically different from traditional kratom leaf and may carry greater risk for dependence, withdrawal, and overdose.
- In July 2026, the DEA announced temporary federal Schedule I control of 7-OH and several related substances, while distinguishing them from botanical kratom products containing naturally occurring 7-OH below the specified threshold.
The Bigger Picture: A Synthetic Turning Point
The 2026 global drug landscape is increasingly defined by a shift away from plant-based opioids and toward novel synthetic and semi-synthetic opioids. International drug reports have warned that reductions in traditional opium and heroin supply can create market pressure for new synthetic alternatives.
The kratom-derivative story in the United States is a domestic example of that same pattern. These compounds are not fentanyl or nitazenes, but they reflect the same structural problem: when a regulatory gray area exists, chemistry can move faster than public health systems, law enforcement, product labeling, and clinical education.
Concentrated 7-OH, MGM-15, and related semi-synthetic kratom derivatives show how quickly a botanical market can shift into an opioid-like synthetic drug market. Traditional kratom leaf contains naturally occurring alkaloids, including mitragynine and trace levels of 7-OH. By contrast, many new products are manufactured to contain elevated concentrations of opioid-active compounds that do not resemble normal kratom leaf exposure.
What Is MGM-16?
MGM-16, also known as 9-fluoro-7-hydroxymitragynine, is a semi-synthetic opioid compound built on the chemical scaffold of mitragynine, the main alkaloid in the kratom plant. It is not a natural component of kratom leaf.
Like its close relative MGM-15, MGM-16 was first described in medicinal-chemistry research as an orally active compound affecting opioid receptors. The key issue for public health is that these compounds are not simply “strong kratom.” They are chemically modified opioid-active derivatives with a different risk profile from traditional botanical kratom.
Origin: MGM-16 is a lab-synthesized derivative related to 7-hydroxymitragynine and mitragynine chemistry.
Potency: Preclinical research has characterized MGM-16 as highly potent in animal models. Human potency comparisons have not been established.
Mechanism: MGM-16 is pharmacologically opioid-active. It should not be framed as a botanical supplement.
An Important Distinction: MGM-16 vs. What Is Actually on Shelves
It is important to be precise because marketing around these products often blurs the line between kratom leaf, kratom extract, concentrated 7-OH, and semi-synthetic kratom derivatives.
The products consumers are most likely to encounter today are concentrated 7-OH products sold as tablets, gummies, drink shots, powders, or branded alkaloid products. Since late 2025, public health concern has also increased around MGM-15. MGM-16 itself has not been widely identified as an established retail product, but it was named by Florida officials because it belongs to the same high-risk chemical family.
In other words, MGM-16 represents how potent this chemical family can become, while 7-OH and MGM-15 are more directly relevant to current consumer exposure.
Comparison of 7-OH-Related Compounds Named in Florida’s Emergency Rule
Florida’s June 2026 emergency rule did not target only 7-hydroxymitragynine. It also named several related natural, modified, and semi-synthetic compounds that have emerged in concentrated 7-OH product discussions. Although these substances share a chemical relationship, they differ in origin, available research, and how they have appeared in commercial products.
| Compound | Also known as | Found naturally? | Reported opioid activity* | Known commercial products / brands** |
|---|---|---|---|---|
| 7-Hydroxymitragynine | 7-OH | Yes, trace alkaloid in kratom | High | Hydroxy, 7Tabz, Roxy 7-OH, 7OHMZ, 777 Jackpot Alkaloids, and other concentrated 7-OH products |
| Mitragynine pseudoindoxyl | Pseudoindoxyl | No | Very high in preclinical research | No established retail brands identified |
| 7-Acetoxymitragynine | 7-acetoxy | No | Under investigation | No established retail brands identified |
| 9-Hydroxycorynantheidine | 9-HC | No | Limited published data | No established retail brands identified |
| 10-Hydroxycorynantheidine | 10-HC | No | Limited published data | No established retail brands identified |
| MGM-15 | Dihydro-7-hydroxymitragynine, DHM | No | Higher than 7-OH in preclinical studies | Reported in designer-drug and concentrated kratom-derivative discussions; no stable mainstream brand list should be assumed |
| MGM-16 | 9-Fluoro-7-hydroxymitragynine | No | Very high in preclinical research | No established retail brands identified |
*Reported opioid activity summarizes laboratory and preclinical findings. Human potency comparisons have not been established for most of these compounds.
**Brand examples refer to products marketed as concentrated 7-OH products. Product names, formulations, and ingredients frequently change. Listing a brand does not confirm that it currently contains a specific compound or concentration.
Why Officials Are Sounding the Alarm
The concern is straightforward: opioid-active compounds are being sold in formats that can look like supplements, candy, or convenience-store wellness products. Many consumers do not understand that concentrated 7-OH products may behave more like opioids than traditional kratom leaf.
The risks include:
- Rapid tolerance
- Physical dependence
- Opioid-like withdrawal
- Respiratory depression
- Overdose risk, especially when combined with alcohol or sedatives
- Relapse risk for people with opioid use disorder
- Misleading labeling or unclear alkaloid concentration
This creates a public-health problem for families, clinicians, emergency departments, poison centers, and addiction treatment programs. A person may believe they are taking a kratom product but may actually be using a concentrated opioid-like alkaloid product.
Florida’s 2026 Emergency Rule
On June 22, 2026, Florida Attorney General James Uthmeier signed an emergency rule controlling highly concentrated 7-OH and related chemical products as Schedule I controlled substances under Florida law.
The Florida Attorney General’s Office stated that the rule covers:
- 7-hydroxymitragynine
- Mitragynine pseudoindoxyl
- 7-acetoxymitragynine
- 9-hydroxycorynantheidine
- 10-hydroxycorynantheidine
- MGM-15
- MGM-16
Florida officials emphasized that 7-OH occurs naturally in kratom only in trace amounts, while concentrated products sold in gas stations, vape shops, and online may be far more hazardous. The rule was designed to target concentrated and chemically altered products rather than ordinary botanical kratom leaf.
DEA 2026 Federal Update
On July 1, 2026, the U.S. Drug Enforcement Administration announced that it filed notices to temporarily schedule 7-OH and related substances under Schedule I of the Controlled Substances Act.
The DEA identified the following substances:
- 7-hydroxymitragynine
- Mitragynine pseudoindoxyl
- MGM-15
- MGM-16
The DEA also made an important distinction: the temporary scheduling action does not apply to botanical kratom products containing naturally occurring 7-OH below the specified threshold. Instead, the action targets synthesized products and products containing elevated concentrations of 7-OH.
If You or Someone You Love Is Using 7-OH Products
Because concentrated 7-OH products act on opioid receptors, regular use can lead to genuine opioid-style dependence and withdrawal. People may experience anxiety, sweating, insomnia, muscle aches, nausea, diarrhea, cravings, depression, and inability to stop despite consequences.
Stopping suddenly after heavy use can be difficult. Some people may need medical detox, medication evaluation, or structured treatment. In certain cases, addiction medicine providers may evaluate whether medications such as buprenorphine-naloxone are appropriate, but this should not be attempted without medical supervision.
For more detailed guidance, read these companion resources:
- What Is 7-OH? The Emerging Opioid Threat Addiction Professionals Need to Understand in 2026
- 7-OH Withdrawal: Symptoms, Timeline, and Treatment Considerations
- 7-Hydroxymitragynine and Kratom Withdrawal
- Does Suboxone Help With Kratom Withdrawal?
Related Articles
- What Is 7-OH?
- 7-OH Withdrawal Symptoms and Timeline
- 7-OH, Kratom Withdrawal, and Suboxone
- Suboxone for Kratom Withdrawal
References
- Florida Office of the Attorney General. “Attorney General James Uthmeier Signs Emergency Rule Immediately Scheduling Dangerous 7-OH and Related Compounds as Schedule I Controlled Substances.” June 22, 2026. myfloridalegal.com
- U.S. Drug Enforcement Administration. “DEA to Temporarily Schedule 7-OH and Related Substances to Protect Public Safety.” July 1, 2026.
- Smith KE, Boyer EW, Grundmann O, McCurdy CR, et al. “The rise of novel, semi-synthetic 7-hydroxymitragynine products.” Addiction.
- Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. “Abuse liability and therapeutic potential of the Mitragyna speciosa alkaloids mitragynine and 7-hydroxymitragynine.” Addiction Biology.
Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, or emergency advice. If you are experiencing a medical emergency, call 911. If someone may be overdosing, administer naloxone if available and seek emergency medical care immediately. If you are struggling with 7-OH, kratom, opioids, or withdrawal symptoms, contact a licensed medical or addiction professional.